Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: ChimeriVax-DEN, Acambis/Aventis.

Taff Jones1

  • 1ID Biomedical Corp, 7150 Frederick Banting, Montreal, H4S 2A1, Quebec, Canada. tjones@idbiomedical.com

Current Opinion in Molecular Therapeutics
|October 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of nasal IgA in children vaccinated with live attenuated influenza vaccine.

Vaccine·2012
Same author

Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.

PloS one·2010
Same author

Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection.

Current opinion in investigational drugs (London, England : 2000)·2010
Same author

GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.

Current opinion in molecular therapeutics·2009
Same author

IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection.

Current opinion in molecular therapeutics·2009
Same author

IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Current opinion in molecular therapeutics·2008

A new dengue virus vaccine, using a chimeric approach based on the yellow fever vaccine, is currently in early-stage human trials. This innovative vaccine aims to prevent dengue virus infections.

Area of Science:

  • Virology
  • Vaccinology
  • Infectious Diseases

Background:

  • Dengue virus infection poses a significant global health challenge.
  • Existing dengue vaccines have limitations, necessitating novel approaches.
  • Chimeric vaccines offer a promising strategy for infectious disease prevention.

Purpose of the Study:

  • To evaluate the safety and immunogenicity of a novel chimeric vaccine for dengue virus prevention.
  • To assess the potential of a recombinant yellow fever vaccine platform for dengue prophylaxis.

Main Methods:

  • Development of a chimeric vaccine combining dengue and yellow fever virus components.
  • Conducting Phase I clinical trials to assess vaccine safety and immune response in human subjects.

Related Experiment Videos

Main Results:

  • The chimeric vaccine is currently undergoing Phase I clinical trials.
  • Preliminary data on safety and immunogenicity are being collected.

Conclusions:

  • The development of this chimeric vaccine represents a potential advancement in dengue prevention strategies.
  • Further clinical evaluation is required to establish the efficacy of this novel vaccine candidate.